Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency

NCT07227207 is registered in ClinicalTrials.gov with Tessera Therapeutics, Inc. as lead sponsor.

NCT NCT07227207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency
Lead sponsor
Tessera Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 21, 2026
Completion date
March 31, 2029
Enrollment
72 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency (aatd)